Glioma Group

Dr Chris Jones’ group investigates ways to translate basic molecular pathology findings into improved clinical outcomes for children with cancer.

Our group is primarily focused on high grade gliomas which arise in children, either supratentorially, or within the brainstem.

The Jones laboratory is primarily focused on high grade gliomas which arise in children, either supratentorially, or within the brainstem. These tumours appear to have key biological and clinical distinctions, both to each other, and histologically similar lesions in adults.

To this end we have current projects focussed on:

  • Genomic and epigenomic profiling of glial tumours of childhood, including large retrospective studies, prospective clinical trial cohorts, and rare entities such as infant glioma and gliomatosis cerebri
  • Model development and preclinical screening of paediatric glioma subgroups, with specific projects focussing on the development of novel therapies directed against ACVR1, histone H3.3 G34R/V and ATRX mutations
  • Intratumoral heterogeneity and subclonal co-operation between distinct cancer stem cell subpopulations, with a view to using disruption of these interactions as a novel area for therapeutic intervention


High-grade gliomas in children share similar histopathological features and a dismal prognosis to those that arise in adults, with a median survival of 15-18 months for cerebral hemispheric tumours and 9-12 months for diffuse intrinsic pontine glioma (DIPG).

Bulk tumour molecular profiling has recently provided important insights into the biological differences associated with high grade gliomas arising at different ages and in different locations.

We and others have identified unique genetic drivers of paediatric high-grade glioma, not present in the adult disease, which illustrate previously unappreciated connections between chromatin regulation, developmental signalling and cancer.

Distinct anatomical distributions of childhood tumours marked by these specific driver mutations points at important differences in the selective pressures vary between regions of the developing brain.

One of the primary goals of my laboratory is to better understand the function of these genetic alterations in the context of paediatric gliomagenesis and to use this mechanistic insight to develop novel therapies for children with these tumours.

Professor Chris Jones

Interim Head of Division:

Glioma Professor Chris Jones

Chris Jones is the Interim Head of Division for Molecular Pathology and heads the Glioma Group whose research aims to find the genes which drive the development of childhood brain tumours. He is Professor of Childhood Brain Tumour Biology, and Preclinical Chair of the international CONNECT consortium.

Researchers in this group

.

Phone: +44 20 3437 6957

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6664

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Dr Julia Cockle is an NIHR-funded Academic Clinical Lecturer at the Institute of Cancer Research. She works as part of the Glioma Group, and her research explores the tumour immune microenvironment of paediatric brain tumours in order to facilitate selection of immunotherapies.

.

Phone: +44 20 3437 6070

Email: [email protected]

Location: SuttonChelsea

.

Phone: +44 20 3437 6384

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4540

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3635

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4138

Email: [email protected]

Location: Sutton

I am Executive Assistant to Professor Chris Jones, Interim Head of the Division of Molecular Pathology. I also act as the liaison point for the Divisional Team Leaders and their teams to ensure smooth running of the administration and oversight of the Division.

.

Phone: +44 20 3437 6165

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6199

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Chelsea

.

Phone: +44 20 8722 4225

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6169

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6176

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3649

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6166

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Haider Tari profile picture .

Email: [email protected]

Location: Sutton

Professor Chris Jones's group have written 192 publications

Most recent new publication 12/2024

See all their publications

Recent discoveries from this group

27/02/23

Human DIPG cells (orange) grown on a mouse brain 'slice' (light blue), treated with the drug combination, trametinib and dasatinib and showing cells dying in the middle.

Scientists have shed light on how different types of cancer cells in an aggressive childhood brain cancer interact and work together to spread.

Using mathematical modelling, the team provides a framework for detecting, measuring and mapping interactions between different types of cells in diffuse intrinsic pontine glioma (DIPG) – a brain tumour starting in a type of cell known as ‘immature glial progenitor cells’ before spreading to other parts of the brain.

Researchers at The Institute of Cancer Research, London, led the study, published in Cell Reports.

They hope targeting and blocking interactions that allow cells to work together to invade surrounding areas could become a new treatment strategy, which is urgently needed in this currently incurable childhood cancer.

Cells within tumours cooperate

DIPG tumours are made up of more than one subtype of cancer cell. In 2018, the team of scientists at The Institute of Cancer Research (ICR) found the first evidence that different subtypes of cells within a tumour can cooperate – rather than solely compete for resources, as was the common belief.  

Their new findings show for the first time that some subtypes have a positive effect on others in terms of how the cells spread – opening up new avenues for testing and developing treatments for this childhood cancer.

The study, funded by Cancer Research UK, explored the interaction between two different subtypes of cancer cells – labelled VI-E6 and VI-D10 - obtained from donated tissue from patient biopsies, when grown together in the lab. The VI-E6 subtype was able to spread further when grown in a co-culture with VI-D10.

Cooperation more than doubled the spread

Using deep learning to process images from experiments in the lab, scientists were able to identify interactions where one cell subtype cooperated and helped the other grow and spread – and differentiate between these interactions and those where one subtype spread more than the other due to other unrelated factors, such as space restrictions.

Previous models exploring cooperation between cancer cells focused on growth, but this innovative study is the first to measure interactions that affect the way tumour cells spread and invade surrounding areas.

Researchers demonstrated that cells behaved differently when cultured together in the lab, rather than in separate environments. Culturing two different subtypes together more than doubled the spread of the tumour.

When they grew the two different cell subtypes together, researchers found cancer cells were able to spread and invade a greater area. While one subtype travelled and spread more quickly, the speed of the other decreased – highlighting commensal interactions, where one subtype gains benefit without harming or benefitting the other, as well as exploitative interactions, where the fitness of one subtype is enhanced while reducing the fitness of the exploited subtype.

Towards more and better personalised treatment options

The findings demonstrate that interactions between DIPG cell subtypes play a key role in helping tumours invade the local environment and spread – adding to our understanding of how this childhood cancer progresses.

In this way, researchers provide a framework which could be applied to more cancer types. By providing a method of identifying and measuring these cell interactions, the effect of treatments can also be explored.

Researchers are increasingly aware of the importance differences between cancer cells within a single tumour can have on treatment outcomes. Their hope is that identifying and measuring interactions between cancer cell subtypes could lead to better and more personalised treatment options.

The study was co-led by Professor Chris Jones and Professor Andrea Sottoriva, former Team Leader at the Centre for Evolution and Cancer at the ICR.

Attacking tumours by 'disrupting positive interactions'

Study co-leader Professor Chris Jones, Professor of Childhood Brain Tumour Biology at The Institute of Cancer Research, London, said:

“This childhood cancer is incredibly difficult to treat. Nearly all children with DIPG die within two years, and new treatments are urgently needed.

“We are beginning to decipher how different types of cells in DIPG interact and work with each other to fuel the disease.

“By combining deep learning and advanced mathematical modelling with experimental data, we provide a framework for detecting, measuring and mapping these interactions – which we hope will lead to new ways of testing and developing treatments that attack tumours by disrupting positive interactions and promoting negative interactions between cell subtypes.”

'Stopping cancer in its tracks'

Study author Dr Haider Tari, who was part of the Evolutionary Genomics and Modelling Team at The Institute of Cancer Research, London, said:

If one subtype cooperates with a different subtype in a way that drives the tumour’s growth and spread, it would be crucial to target and block this cooperation – with the goal of stopping cancer in its tracks.

“This innovative study provides a way to identify whether cells are interacting and by how much, and the framework could be applied to a number of different cancer types."

'Discovery research brings hope'

Dr Laura Danielson, Children’s and Young People’s Research Lmoead at Cancer Research UK, said:

“This study demonstrates the power of mathematical modelling to better understand how cancer cells interact and spread.

“More work needs to be done to understand how we could potentially target these interactions, but discovery research like this brings hope for development of more effective treatments for children and young people affected by cancer.”